Tag Archives | HCV

Large Cap Biopharma Earnings Boost Stocks: Update 8/1/17

Rayno Large Cap Biopharma Earnings Summary 8/1/17 Biotech Stocks Hit Highs in Mid-July up 18%, 30% on XBI (Click on “urls” below for Company Press Release) All the large cap biopharmaceutical earnings have come in except Regeneron (REGN) which will report on August 3.  Stocks were broadly higher in July after financial reports, however we suggested […]

Continue Reading 0

Rayno BioBeat #4: Biotechs Weaken on Profit Taking…Update-2

Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and suggested last week […]

Continue Reading 0

2017 Life Science Review #1: Big Biotech Gains for First Half

Big Biotech Gains for Stocks in First Half Rayno Life Science Picks Top Winners YTD: Foundation Medicine (FMI) up 124.6%, bluebird bio (BLUE) up 70.26%, XBI up 20.9%. Large cap winners since inception: Abbvie (ABBV) and Roche ADR (RHHBY). 6/27 Take some profits on XBI at $78. XBI is our top ETF pick. XLV SPDR […]

Continue Reading 0

Rayno Life Science Portfolio 2017

Update-1 6/27/17 With the XBI up 34% YTD at $79.34, take a little off for future trades. ===== Rayno Life Science Portfolio 2017 YTD 6/15 Top winners YTD: BLUE up 78.9%,FMI up 121.5%,RHHBY up 13%, ABBV up 12.7%. Top Losers YTD: GILD down 9.5%, BMY down 7%. XBI up 20.9%, our top pick for aggressive […]

Continue Reading 0

Biotechs Sink Again in Sector Shift to Technology Stocks: Update-1

6/1/17 Update at close…Biotechs Bounce off Bottom of 3 Month Trading Range IBB up 1.8% back above $290 after hitting 200 SMA bottom. XBI up 2.7% to $69.54 at SMA 50. XBI 2017 top is $72. XLV a safer play up over 1% to $76.91; above March highs and near 12 mo. highs up 11.58% […]

Continue Reading 0

Large Cap Biopharmaceutical Valuations: Q1 2017

May 8, 2017  Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%.  The large cap focused IBB […]

Continue Reading 0

Rayno Biobeat #3 2017 Biotech Breakout Coming-Update-2

Update: Big Down Day in Biotech XBI down 3% Article to follow: big movers down CELG,KITE, PBYI, TSRO, XLRN etc Update-1… 5/8/17…Biotech Sector Losing Momentum XBI down 4.3% over 5 days although still up 15.5% YTD. IBB very weak today down over 2%. NASDAQ Composite and QQQ holding near highs mainly because of strength in […]

Continue Reading 0

Biotech Sector Leads Market Early in 2017 Despite Uncertainties…Update

Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at $287.67 breaking the $290 technical level not seen since […]

Continue Reading 0

Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1

Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the red except ALXN,BIIB […]

Continue Reading 2

Biotech Recap: Rally Continues with Strong Tape…Update-1

Update-1 2/16… Profit Taking Day-Momentum Eases IBB,XBI down ~0.65% Large caps mixed: AMGN,GILD,MRK,RHHBY in green; REGN down 2.86%. Alexion (ALXN) down 1.22% on earnings and guidance. Misses on Revs but up 18.5%. Mid Caps in the red: GWPH down 2%; ICPT down 2.26%, RDUS down 6%.Big  Movers Up on News: Agios (AGIO) up 8%, Esperion (ESPR) […]

Continue Reading 0